Winestone Lena E, Getz Kelly D, Miller Tamara P, Wilkes Jennifer J, Sack Leah, Li Yimei, Huang Yuan-Shung, Seif Alix E, Bagatell Rochelle, Fisher Brian T, Epstein Andrew J, Aplenc Richard
Division of Oncology, The Children's Hospital of Philadelphia, Pennsylvania.
Center for Pediatric Clinical Effectiveness, The Children's Hospital of Philadelphia, Pennsylvania.
Am J Hematol. 2017 Feb;92(2):141-148. doi: 10.1002/ajh.24605. Epub 2016 Dec 7.
Black patients with acute myeloid leukemia (AML) experience higher mortality than White patients. We compared induction mortality, acuity of illness prior to chemotherapy, and insurance type between Black and White patients to assess whether acuity of presentation mediates the disparity. Within a retrospective cohort of 1,122 children with AML treated with two courses of standard induction chemotherapy between 2004 and 2014 in the Pediatric Health Information System (PHIS) database, the association between race (Black versus White) and inpatient mortality during induction was examined. Intensive Care Unit (ICU)-level resource utilization during the first 72 hours following admission for initial AML chemotherapy was evaluated as a potential mediator. The total effect of race on mortality during Induction I revealed a strong association (unadjusted HR 2.75, CI: 1.18, 6.41). Black patients had a significantly higher unadjusted risk of requiring ICU-level resources within the first 72 hours after initial presentation (17% versus 11%; RR 1.52, CI: 1.04, 2.24). Mediation analyses revealed the indirect effect of race through acuity accounted for 61% of the relative excess mortality during Induction I. Publicly insured patients experienced greater induction mortality than privately insured patients regardless of race. Black patients with AML have significantly greater risk of induction mortality and are at increased risk for requiring ICU-level resources soon after presentation. Higher acuity amongst Black patients accounts for a substantial portion of the relative excess mortality during Induction I. Targeting factors affecting acuity of illness at presentation may lessen racial disparities in AML induction mortality.
急性髓系白血病(AML)黑人患者的死亡率高于白人患者。我们比较了黑人和白人患者的诱导缓解期死亡率、化疗前疾病的严重程度以及保险类型,以评估疾病严重程度是否介导了这种差异。在2004年至2014年期间,对儿科健康信息系统(PHIS)数据库中接受两个疗程标准诱导化疗的1122例AML儿童患者进行回顾性队列研究,考察种族(黑人与白人)与诱导缓解期住院死亡率之间的关联。将初始AML化疗入院后前72小时内重症监护病房(ICU)级别的资源利用情况作为潜在的中介因素进行评估。种族对诱导缓解期I死亡率的总体影响显示出强烈的关联(未调整的风险比为2.75,置信区间:1.18,6.41)。黑人患者在初次就诊后前72小时内需要ICU级别资源的未调整风险显著更高(17%对11%;风险比1.52,置信区间:1.04,2.24)。中介分析显示,种族通过疾病严重程度产生的间接影响占诱导缓解期I相对超额死亡率的61%。无论种族如何,参加公共保险的患者诱导缓解期死亡率均高于参加私人保险的患者。AML黑人患者诱导缓解期死亡风险显著更高,且就诊后不久需要ICU级别资源的风险增加。黑人患者较高的疾病严重程度占诱导缓解期I相对超额死亡率的很大一部分。针对影响就诊时疾病严重程度的因素可能会减少AML诱导缓解期死亡率的种族差异。